US 12,233,068 B2
Combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
Franziska Elena Herrmann, Weilheim (DE); Peter Nickolaus, Warthausen (DE); and Stefan Ludwig Michael Wollin, Bad Waldsee (DE)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Jun. 29, 2023, as Appl. No. 18/343,792.
Application 18/343,792 is a continuation of application No. 17/811,914, filed on Jul. 12, 2022, granted, now 11,813,266.
Application 17/811,914 is a continuation of application No. 16/166,239, filed on Oct. 22, 2018, granted, now 11,406,638, issued on Aug. 9, 2020.
Claims priority of application No. 17197719 (EP), filed on Oct. 23, 2017.
Prior Publication US 2023/0405010 A1, Dec. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 31/496 (2006.01); A61K 31/505 (2006.01); A61P 11/00 (2006.01); A61P 21/00 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/496 (2013.01); A61K 31/505 (2013.01); A61P 11/00 (2018.01)] 6 Claims
OG exemplary drawing
 
1. A method of treating systemic sclerosis ILD (SSc-ILD), comprising administering to a patient in need thereof a therapeutically effective amount of a PDE4B-inhibitor of formula

OG Complex Work Unit Chemistry
III,
wherein S* is a sulphur atom that represents a chiral center,
or a pharmaceutically acceptable salt thereof,
and a therapeutically effective amount of a tyrosine kinase inhibitor selected from the group consisting of Nintedanib and pharmaceutically acceptable salts thereof.